Pino Marta Del, Matas Isabel, Carrillo Pilar, Martí Cristina, Glickman Ariel, Carreras-Dieguez Núria, Marimon Lorena, Saco Adela, Rakislova Natalia, Torné Aureli, Ordi Jaume
Institute Clinic of Gynecology, Obstetrics, and Neonatology, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Cancers (Basel). 2023 Feb 10;15(4):1147. doi: 10.3390/cancers15041147.
Women with high-grade squamous intraepithelial lesions/cervical intraepithelial neoplasia (HSIL/CIN) are at high risk of anal human papillomavirus HPV infection, and it has also been suggested that self-inoculation of the virus from the anal canal to the cervix could explain HPV recurrence in the cervix after treatment of HSIL/CIN. We aimed to evaluate the bidirectional interactions of HPV infection between these two anatomical sites. We evaluated 68 immunocompetent women undergoing excisional treatment for HSIL/CIN. Immediately before treatment, samples from the anus and the cervix were obtained (baseline anal and cervical HPV status). Cervical HPV clearance after treatment was defined as treatment success. The first follow-up control was scheduled 4-6 months after treatment for cervical and anal samples. High resolution anoscopy (HRA) was performed on patients with persistent anal HPV infections or abnormal anal cytology in the first control. Baseline anal HPV was positive in 42/68 (61.8%) of the women. Anal HPV infection persisted after treatment in 29/68 (42.6%) of the women. One-third of these women (10/29; 34.5%) had HSIL/anal intraepithelial neoplasia (AIN). Among women achieving treatment success, cervical HPV in the first control was positive in 34.6% and 17.6% of the patients with positive and negative baseline anal HPV infection, respectively ( = 0.306). In conclusion, patients with persisting anal HPV after HSIL/CIN treatment are at high risk of HSIL/AIN, suggesting that these women would benefit from anal exploration. The study also suggests that women with anal HPV infection treated for HSIL/CIN might be at higher risk of recurrent cervical HPV even after successful treatment.
患有高级别鳞状上皮内病变/宫颈上皮内瘤变(HSIL/CIN)的女性存在肛门人乳头瘤病毒(HPV)感染的高风险,并且也有人提出病毒从肛管自我接种至宫颈可以解释HSIL/CIN治疗后宫颈HPV的复发。我们旨在评估这两个解剖部位之间HPV感染的双向相互作用。我们评估了68名接受HSIL/CIN切除治疗的免疫功能正常的女性。在治疗前即刻,获取肛门和宫颈的样本(基线肛门和宫颈HPV状态)。治疗后宫颈HPV清除被定义为治疗成功。首次随访对照安排在治疗后4 - 6个月,用于采集宫颈和肛门样本。对首次对照中肛门HPV持续感染或肛门细胞学异常的患者进行高分辨率肛门镜检查(HRA)。68名女性中有42名(61.8%)基线肛门HPV呈阳性。68名女性中有29名(42.6%)在治疗后肛门HPV感染持续存在。这些女性中有三分之一(10/29;34.5%)患有HSIL/肛门上皮内瘤变(AIN)。在治疗成功的女性中,首次对照时,基线肛门HPV感染阳性和阴性的患者中宫颈HPV阳性率分别为34.6%和17.6%(P = 0.306)。总之,HSIL/CIN治疗后肛门HPV持续存在的患者有发生HSIL/AIN的高风险,提示这些女性将从肛门探查中获益。该研究还表明,因HSIL/CIN接受治疗的肛门HPV感染女性即使在治疗成功后仍可能有更高的宫颈HPV复发风险。